Last week’s decision by the National Cancer Institute to permit individual principal investigators to purchase access to Celera’s database was hailed by Celera and NCI alike as a conciliatory conclusion to the often ugly rivalry between the company and the publicly funded Human Genome Project.

“In some ways, it’s a validation of the American way, which is to start competition,” said Stephen O’Brien, chief of the NCI’s laboratory of genomic diversity.